0.04Open0.04Pre Close0 Volume291 Open Interest2.00Strike Price0.00Turnover0.00%IV163.57%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma19.36Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Ocugen Stock Discussion
GlobeNewswire· 5 mins ago
OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular Inflammation, anterior ischemic optic neuropathy, or vasculitis
Grabbed a few at .88. It usually hovers around $1-2, a little upside
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
No comment yet